This trial is testing a new cancer drug to see if it is safe and effective.
7 Primary · 13 Secondary · Reporting Duration: Up to 24 months
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: CAB-AXL-ADC · No Placebo Group · Phase 1 & 2
Age Any Age · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: